IRLAB Therapeutics AB (publ) (IRLAB_A) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to this live Q2 presentation by research company iLab addressing Parkinson and other CNS diseases. Presenting today is CEO Kristina Torfgård, Vice President Research and Development Niklas Waters and CFO Victor Sievert. After the presentation there will be a Q&A with equity analysts and viewers can ask their questions in the live chat. I hereby welcome CEO Kristina Torfgård and please go ahead with your presentation. Thank you very much, Mattias. So this is our disclaimer and we are listed on Nasdaq Stockholm main market to remind about that. Very pleased to have you all listening in today. Can I have the first slide there? Thank you. Which is the agenda for today. So I will start with some news during the period. Hand over to Nicolas, EVP, head of R&D, to take you through the R&D update. And after that, we will hear Victor Sievers, our CFO, to take you through the financials. And then I will come back in there and talk and make some concluding words. And this will be then followed by a Q&A session, as you already heard. So we have had a very good period also this time. We are very excited about the progress we are doing with the projects. First here, I have summarized a couple of the key highlights that we think are very important for the company during the period and after. We have a new patent granted for Mestopetan, which is the SALT patent, which is used for the drug product for the candidates that we are developing and using in the studies. This patent will be extended until and through mid And this is specifically in the US, which makes that we have a really good impact in a huge market. And this is already granted in many of the other countries all over the world. So this will also strengthen our value proposition for the candidate. And we believe tha...